Ads
related to: astrazeneca oncology r&d careers in houston near meLarge Employment Site (>10 Million Unique Visitors Per Month) - TAtech
us.catchwork.jobs has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
The AstraZeneca R&D facility in Mölndal near Gothenburg, Sweden The new AstraZeneca Corporate HQ under construction in Cambridge, United Kingdom AstraZeneca develops, manufactures and sells pharmaceutical and biotechnology products to treat disorders in the oncology , cardiovascular , gastrointestinal , infection , neuroscience , respiratory ...
For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363). AstraZeneca Media Inquiries:
Dulles Technology Corridor: Northern Virginia near Washington Dulles Airport; Greater Seattle; Golden Corridor: Near Chicago's O'Hare International Airport and Northwest Suburbs; Greater Reno, Nevada; I-270 Technology Corridor (also known as "DNA Alley"): [19] Area in central Montgomery County, Maryland, in the northern suburbs of Washington, D ...
The collaboration between the MD Anderson Cancer Center in Houston and Tata Memorial Hospital (TMH) in Mumbai, India is a significant partnership aimed at enhancing cancer research, education, and clinical care. Established in 2003, this sister institution accord was facilitated by the Indo-American Chamber of Commerce of Greater Houston.
Biogen was founded in 1978 in Geneva as Biotechnology Geneva by several prominent biologists, including Kenneth Murray from the University of Edinburgh, Phillip Allen Sharp from the Massachusetts Institute of Technology, Walter Gilbert from Harvard University (Gilbert served as CEO during the start-up phase of Biogen), Heinz Schaller from the University of Heidelberg, and Charles Weissmann ...
In October 2013, Merck announced it would cut 8,500 jobs in an attempt to cut $2.5 billion from its costs by 2015. Combined with 7,500 job cuts announced in 2011 and 2012, the layoffs amounted to 20% of its workforce. [86] [87] By 2014, research performed at Merck has led to U.S. FDA approval of 63 new molecular entities. [88]